THE LONG-TERM OBJECTIVE OF THE PROPOSAL IS TO CREATE AND EVALUATE THE EFFECTIVENESS OF MONOCLONAL ANTIBODY DIRECTED AGAINST THE RECEPTOR ON MALIGNANT CELLS RECOGNIZED BY ACTIVATED MACROPHAGES.

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1985
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
3018
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Biological Therapeutics, Inc.
3505 Riverview Circle, Moorhead, MN, 56560
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
JAMES R. HOFFMAN
PRINCIPAL INVESTIGATOR
(218) 236-7648
Business Contact:
() -
Research Institution:
n/a
Abstract
THE LONG-TERM OBJECTIVE OF THE PROPOSAL IS TO CREATE AND EVALUATE THE EFFECTIVENESS OF MONOCLONAL ANTIBODY DIRECTED AGAINST THE RECEPTOR ON MALIGNANT CELLS RECOGNIZED BY ACTIVATED MACROPHAGES. MACROPHAGES, WHEN ACTIVATED, RECOGNIZE AND DESTROY MALIGNANT CELLS. ACTIVATED MACROPHAGES DO NOT RECOGNIZE NONMALIGNANT CELLS. THE NATURE OF THIS RECEPTOR SITE IS UNKNOWN. IN THE CURRENT PHASE I PROPOSAL, USING NOVEL IMMUNIZATION PROTOCOLS, MONOCLONAL ANTIBODY WILL BE PRODUCED TO THAT RECOGNITION SITE. THE ANTIBODY WILL BE SCREENED IN APPROPRIATE ASSAYS FOR REACTIVITY WITH MALIGNANT AND NORMAL CELLS, INHIBITION OF BINDING, AND IMMUNOMODULATION. SUBSEQUENT PHASE II DEVELOPMENT WILL EVALUATE ITS ABILITY TO DESTROY TUMOR CELLS IN MODEL SYSTEMS BY VARIOUS MECHANISMS INCLUDING DIRECT TOXICITY, ANTIBODY-DEPENDENT CYTOTOXICITY AND THOROUGH IMMUNOTOXICITY CONJUGATES. ADDITIONAL DEVELOPMENT WOULD BE TO PROCEED TO PHASE I CLINICAL TRIALS. ALTERNATIVELY, THE ANTIBODY MAY BE USED TO PURIFY THE RECOGNITION SITE AND DEVELOP, USING THAT ANTIGEN, HUMAN MONOCLONAL ANTIBODIES.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government